[go: up one dir, main page]

MA39108A1 - Nouveau composé pour le traitement de l'hypoglycémie sévère - Google Patents

Nouveau composé pour le traitement de l'hypoglycémie sévère

Info

Publication number
MA39108A1
MA39108A1 MA39108A MA39108A MA39108A1 MA 39108 A1 MA39108 A1 MA 39108A1 MA 39108 A MA39108 A MA 39108A MA 39108 A MA39108 A MA 39108A MA 39108 A1 MA39108 A1 MA 39108A1
Authority
MA
Morocco
Prior art keywords
treatment
new compound
severe hypoglycaemia
hypoglycaemia
severe
Prior art date
Application number
MA39108A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Robert Chadwick Cummins
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52278803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39108(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39108A1 publication Critical patent/MA39108A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Removal Of Specific Substances (AREA)

Abstract

La présente invention concerne un nouveau composé utile dans le traitement de l'hypoglycémie.
MA39108A 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie sévère MA39108A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917658P 2013-12-18 2013-12-18
PCT/US2014/069646 WO2015094878A1 (fr) 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie sévère

Publications (1)

Publication Number Publication Date
MA39108A1 true MA39108A1 (fr) 2017-11-30

Family

ID=52278803

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39108A MA39108A1 (fr) 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie sévère

Country Status (26)

Country Link
US (1) US9688736B2 (fr)
EP (1) EP3083669A1 (fr)
JP (1) JP2017503782A (fr)
KR (1) KR20160077215A (fr)
CN (1) CN105793282A (fr)
AP (1) AP2016009268A0 (fr)
AR (1) AR098616A1 (fr)
AU (1) AU2014366427B2 (fr)
BR (1) BR112016012505A2 (fr)
CA (1) CA2928987A1 (fr)
CL (1) CL2016001473A1 (fr)
CR (1) CR20160223A (fr)
DO (1) DOP2016000128A (fr)
EA (1) EA201691036A1 (fr)
EC (1) ECSP16024805A (fr)
HK (1) HK1224303A1 (fr)
IL (1) IL245399A0 (fr)
MA (1) MA39108A1 (fr)
MX (1) MX2016007984A (fr)
NZ (1) NZ719451A (fr)
PE (1) PE20160787A1 (fr)
PH (1) PH12016501184A1 (fr)
SG (1) SG11201604232TA (fr)
TN (1) TN2016000180A1 (fr)
TW (1) TW201609129A (fr)
WO (1) WO2015094878A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (fr) 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
EP3921336B1 (fr) 2019-02-05 2023-03-01 Eli Lilly And Company Agonistes analogiques du glucagon et leurs procédés d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124974B1 (fr) * 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Analogues de glucagon présentant une solubilité améliorée dans des tampons à ph physiologiques
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
MX337038B (es) 2008-06-17 2016-02-10 Univ Indiana Res & Tech Corp Co-antagonistas de receptor de glucagon/glp-1.
CN104447980A (zh) * 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
AU2011206979B2 (en) 2010-01-20 2015-09-10 Zealand Pharma A/S Treatment of cardiac conditions
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
JP2013523620A (ja) * 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
RU2559320C2 (ru) * 2010-03-26 2015-08-10 Ново Нордиск А/С Новые аналоги глюкагона
RU2012153753A (ru) 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
CA2796894A1 (fr) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Promedicaments peptidiques a base d'amides de la superfamille du glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
WO2011163473A1 (fr) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Analogues du glucagon présentant une solubilité et une stabilité améliorées dans des tampons à ph physiologique
RU2013133803A (ru) 2010-12-22 2015-01-27 Маркадиа Байотек, Инк. Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
WO2012098462A1 (fr) 2011-01-20 2012-07-26 Zealand Pharma A/S Combinaison d'analogues du glucagon acylé à des analogues d'insuline
US20140031278A1 (en) * 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물

Also Published As

Publication number Publication date
AU2014366427A1 (en) 2016-05-19
EP3083669A1 (fr) 2016-10-26
CL2016001473A1 (es) 2017-03-10
JP2017503782A (ja) 2017-02-02
WO2015094878A1 (fr) 2015-06-25
US20160311883A1 (en) 2016-10-27
DOP2016000128A (es) 2016-06-30
BR112016012505A2 (pt) 2017-09-26
HK1224303A1 (zh) 2017-08-18
SG11201604232TA (en) 2016-07-28
PH12016501184A1 (en) 2016-07-25
ECSP16024805A (es) 2017-02-24
CR20160223A (es) 2016-07-12
EA201691036A1 (ru) 2016-12-30
CN105793282A (zh) 2016-07-20
IL245399A0 (en) 2016-06-30
PE20160787A1 (es) 2016-08-17
AP2016009268A0 (en) 2016-06-30
MX2016007984A (es) 2016-09-09
NZ719451A (en) 2017-10-27
US9688736B2 (en) 2017-06-27
TN2016000180A1 (en) 2017-10-06
AR098616A1 (es) 2016-06-01
AU2014366427B2 (en) 2017-02-16
TW201609129A (zh) 2016-03-16
CA2928987A1 (fr) 2015-06-25
KR20160077215A (ko) 2016-07-01

Similar Documents

Publication Publication Date Title
MA37740A1 (fr) Seringue
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
AR095097A1 (es) Compuestos de fenoxietoxi
MA39110A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA42166A1 (fr) Seringue
MA39108A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie sévère
MA39109B1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside
EA201690214A1 (ru) Способ лечения гипертрофической кардиомиопатии
EA201690593A1 (ru) Новые соединения мочевины
UA113753C2 (xx) Фенілзаміщені кетоеноли для боротьби з паразитами риб
MA38931A1 (fr) Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
EA201600013A1 (ru) Основание ковша и ковш
MA38411B1 (fr) Inhibiteurs de cdc7